688505.SS
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
688505.SS
(2.0)8,35 CNY
4% ROA
4.7% ROE
92.73x PER
1.293.109.181,00 CNY
0.52% DER
0.91% Yield
15.12% NPM
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Stock Analysis
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|---|---|
| 1 |
DER
The stock has a low debt to equity ratio (6%), which means it has a small amount of debt compared to the ownership it holds |
|
| 2 |
Assets Growth
With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance. |
|
| 3 |
ROE
The stock's ROE falls within an average range (6.2%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity. |
|
| 4 |
ROA
The stock's ROA (4.79%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits. |
|
| 5 |
Dividend
Investors can rely on the company's consistent dividend payments over the past three years, offering a steady stream of returns. |
|
| 6 |
Buffet Intrinsic Value
The company's stock seems undervalued (69) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price. |
|
| 7 |
PBV
The stock's elevated P/BV ratio (4.81x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value. |
|
| 8 |
Revenue Growth
Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option. |
|
| 9 |
Net Profit Growth
Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect. |
|
| 10 |
Graham Number
The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity. |
|
| 11 |
Dividend Growth
The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns. |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|---|---|
| 1 | Awesome Oscillator | Hold |
| 2 | MACD | Sell |
| 3 | RSI | Hold |
| 4 | Stoch RSI | Hold |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 2005 | 20.117.000 | |
| 2006 | 19.764.000 | -1.79% |
| 2007 | 24.927.000 | 20.71% |
| 2008 | 31.990.000 | 22.08% |
| 2009 | 61.905.000 | 48.32% |
| 2010 | 92.390.000 | 33% |
| 2011 | 133.890.000 | 31% |
| 2012 | 232.527.000 | 42.42% |
| 2013 | 415.925.000 | 44.09% |
| 2014 | 470.900.000 | 11.67% |
| 2015 | 579.463.000 | 18.74% |
| 2016 | 621.870.000 | 6.82% |
| 2017 | 497.694.000 | -24.95% |
| 2018 | 740.422.000 | 32.78% |
| 2019 | 1.029.294.769 | 28.07% |
| 2020 | 1.042.393.012 | 1.26% |
| 2020 | 833.802.693 | -25.02% |
| 2021 | 1.140.313.088 | 26.88% |
| 2022 | 1.031.159.838 | -10.59% |
| 2023 | 740.531.908 | -39.25% |
| 2023 | 845.342.807 | 12.4% |
| 2024 | 1.035.760.768 | 18.38% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 2005 | 24.438.000 | |
| 2006 | 15.570.000 | -56.96% |
| 2007 | 15.863.000 | 1.85% |
| 2008 | 16.004.000 | 0.88% |
| 2009 | 22.108.000 | 27.61% |
| 2010 | 23.819.000 | 7.18% |
| 2011 | 32.891.000 | 27.58% |
| 2012 | 45.312.000 | 27.41% |
| 2013 | 68.108.000 | 33.47% |
| 2014 | 105.071.000 | 35.18% |
| 2015 | 110.116.000 | 4.58% |
| 2016 | 95.046.000 | -15.86% |
| 2017 | 110.426.000 | 13.93% |
| 2018 | 114.284.000 | 3.38% |
| 2019 | 127.821.947 | 10.59% |
| 2020 | 191.969.988 | 33.42% |
| 2020 | 139.268.429 | -37.84% |
| 2021 | 224.387.287 | 37.93% |
| 2022 | 226.850.903 | 1.09% |
| 2023 | 202.351.572 | -12.11% |
| 2023 | 225.531.824 | 10.28% |
| 2024 | 341.199.004 | 33.9% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 2005 | 12.417.000 | |
| 2006 | 10.726.000 | -15.77% |
| 2007 | 11.309.000 | 5.16% |
| 2008 | 12.156.000 | 6.97% |
| 2009 | 11.848.000 | -2.6% |
| 2010 | 11.124.000 | -6.51% |
| 2011 | 17.371.000 | 35.96% |
| 2012 | 16.810.000 | -3.34% |
| 2013 | 20.772.000 | 19.07% |
| 2014 | 22.650.000 | 8.29% |
| 2015 | 28.876.000 | 21.56% |
| 2016 | 36.485.000 | 20.86% |
| 2017 | 54.509.000 | 33.07% |
| 2018 | 93.579.000 | 41.75% |
| 2019 | 13.391.383 | -598.8% |
| 2020 | 39.008.560 | 65.67% |
| 2020 | 17.428.932 | -123.81% |
| 2021 | 16.410.732 | -6.2% |
| 2022 | 12.947.660 | -26.75% |
| 2023 | 112.752.432 | 88.52% |
| 2023 | 17.276.467 | -552.64% |
| 2024 | 392.405.792 | 95.6% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 2005 | -31.757.000 | |
| 2006 | -15.175.000 | -109.27% |
| 2007 | -21.224.000 | 28.5% |
| 2008 | -15.476.000 | -37.14% |
| 2009 | 253.000 | 6217% |
| 2010 | 14.656.000 | 98.27% |
| 2011 | 46.950.000 | 68.78% |
| 2012 | 72.761.000 | 35.47% |
| 2013 | 119.214.000 | 38.97% |
| 2014 | 154.362.000 | 22.77% |
| 2015 | 180.963.000 | 14.7% |
| 2016 | 184.771.000 | 2.06% |
| 2017 | 118.400.000 | -56.06% |
| 2018 | 202.305.000 | 41.47% |
| 2019 | 318.601.833 | 36.5% |
| 2020 | 284.013.460 | -12.18% |
| 2020 | 225.103.071 | -26.17% |
| 2021 | 253.338.674 | 11.15% |
| 2022 | 194.916.854 | -29.97% |
| 2023 | 139.761.252 | -39.46% |
| 2023 | 139.099.360 | -0.48% |
| 2024 | 272.442.280 | 48.94% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 2005 | 8.024.000 | |
| 2006 | 10.351.000 | 22.48% |
| 2007 | 14.047.000 | 26.31% |
| 2008 | 19.781.000 | 28.99% |
| 2009 | 45.720.000 | 56.73% |
| 2010 | 73.690.000 | 37.96% |
| 2011 | 110.856.000 | 33.53% |
| 2012 | 208.970.000 | 46.95% |
| 2013 | 383.518.000 | 45.51% |
| 2014 | 434.079.000 | 11.65% |
| 2015 | 529.449.000 | 18.01% |
| 2016 | 575.358.000 | 7.98% |
| 2017 | 442.903.000 | -29.91% |
| 2018 | 664.125.000 | 33.31% |
| 2019 | 955.954.266 | 30.53% |
| 2020 | 962.617.596 | 0.69% |
| 2020 | 770.964.176 | -24.86% |
| 2021 | 1.059.357.721 | 27.22% |
| 2022 | 947.097.770 | -11.85% |
| 2023 | 686.966.448 | -37.87% |
| 2023 | 735.988.311 | 6.66% |
| 2024 | 919.777.724 | 19.98% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 2005 | -30.356.000 | |
| 2006 | -22.030.000 | -37.79% |
| 2007 | -29.550.000 | 25.45% |
| 2008 | -23.402.000 | -26.27% |
| 2009 | -7.320.000 | -219.7% |
| 2010 | 3.681.000 | 298.86% |
| 2011 | 30.826.000 | 88.06% |
| 2012 | 53.159.000 | 42.01% |
| 2013 | 87.218.000 | 39.05% |
| 2014 | 118.258.000 | 26.25% |
| 2015 | 127.723.000 | 7.41% |
| 2016 | 138.708.000 | 7.92% |
| 2017 | 75.287.000 | -84.24% |
| 2018 | 150.982.000 | 50.14% |
| 2019 | 227.357.983 | 33.59% |
| 2020 | 223.076.072 | -1.92% |
| 2020 | 164.662.782 | -35.47% |
| 2021 | 213.295.758 | 22.8% |
| 2022 | 137.997.098 | -54.57% |
| 2023 | 85.816.500 | -60.8% |
| 2023 | 108.627.368 | 21% |
| 2024 | 272.502.672 | 60.14% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 2005 | 0 | |
| 2006 | 0 | 0% |
| 2007 | 0 | 0% |
| 2008 | 0 | 0% |
| 2009 | 0 | 0% |
| 2010 | 0 | 0% |
| 2011 | 0 | 0% |
| 2012 | 0 | 0% |
| 2013 | 0 | 0% |
| 2014 | 0 | 0% |
| 2015 | 0 | 0% |
| 2016 | 0 | 0% |
| 2017 | 0 | 0% |
| 2018 | 0 | 0% |
| 2019 | 0 | 0% |
| 2020 | 0 | 0% |
| 2020 | 0 | 0% |
| 2021 | 0 | 0% |
| 2022 | 0 | 0% |
| 2023 | 0 | 0% |
| 2023 | 0 | 0% |
| 2024 | 0 | 0% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 2006 | -38.264.000 | |
| 2007 | -23.460.000 | -63.1% |
| 2008 | -18.806.000 | -24.75% |
| 2009 | -48.092.000 | 60.9% |
| 2010 | -16.514.000 | -191.22% |
| 2011 | 16.601.000 | 199.48% |
| 2012 | -4.506.000 | 468.42% |
| 2013 | 32.066.000 | 114.05% |
| 2014 | 43.454.000 | 26.21% |
| 2015 | 56.548.000 | 23.16% |
| 2016 | 93.752.000 | 39.68% |
| 2017 | -18.230.000 | 614.27% |
| 2018 | 136.150.000 | 113.39% |
| 2019 | 228.846.965 | 40.51% |
| 2020 | 70.592.542 | -224.18% |
| 2021 | 148.783.804 | 52.55% |
| 2022 | 77.964.308 | -90.84% |
| 2023 | -27.952.238 | 378.92% |
| 2023 | 78.938.861 | 135.41% |
| 2024 | -14.041.229 | 662.19% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 2006 | -21.399.000 | |
| 2007 | -17.185.000 | -24.52% |
| 2008 | -15.890.000 | -8.15% |
| 2009 | 7.724.000 | 305.72% |
| 2010 | -7.108.000 | 208.67% |
| 2011 | 49.589.000 | 114.33% |
| 2012 | 110.188.000 | 55% |
| 2013 | 89.442.000 | -23.19% |
| 2014 | 88.359.000 | -1.23% |
| 2015 | 96.296.000 | 8.24% |
| 2016 | 140.574.000 | 31.5% |
| 2017 | 42.711.000 | -229.13% |
| 2018 | 173.939.000 | 75.44% |
| 2019 | 269.232.612 | 35.39% |
| 2020 | 113.003.294 | -138.25% |
| 2021 | 268.899.775 | 57.98% |
| 2022 | 165.268.622 | -62.7% |
| 2023 | 71.015.450 | -132.72% |
| 2023 | 110.466.365 | 35.71% |
| 2024 | -16.288.839 | 778.17% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 2006 | 16.865.000 | |
| 2007 | 6.275.000 | -168.76% |
| 2008 | 2.916.000 | -115.19% |
| 2009 | 55.816.000 | 94.78% |
| 2010 | 9.406.000 | -493.41% |
| 2011 | 32.988.000 | 71.49% |
| 2012 | 114.694.000 | 71.24% |
| 2013 | 57.376.000 | -99.9% |
| 2014 | 44.905.000 | -27.77% |
| 2015 | 39.748.000 | -12.97% |
| 2016 | 46.822.000 | 15.11% |
| 2017 | 60.941.000 | 23.17% |
| 2018 | 37.789.000 | -61.27% |
| 2019 | 40.385.647 | 6.43% |
| 2020 | 42.410.752 | 4.77% |
| 2021 | 120.115.971 | 64.69% |
| 2022 | 87.304.314 | -37.58% |
| 2023 | 98.967.688 | 11.79% |
| 2023 | 31.527.504 | -213.91% |
| 2024 | -2.247.610 | 1502.71% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 2005 | 123.727.000 | |
| 2006 | 101.697.000 | -21.66% |
| 2007 | 71.041.000 | -43.15% |
| 2008 | 75.883.000 | 6.38% |
| 2009 | 168.368.000 | 54.93% |
| 2010 | 168.705.000 | 0.2% |
| 2011 | 201.067.000 | 16.1% |
| 2012 | 260.113.000 | 22.7% |
| 2013 | 565.925.000 | 54.04% |
| 2014 | 676.419.000 | 16.34% |
| 2015 | 765.840.000 | 11.68% |
| 2016 | 873.054.000 | 12.28% |
| 2017 | 892.482.000 | 2.18% |
| 2018 | 993.284.000 | 10.15% |
| 2019 | 933.148.114 | -6.44% |
| 2020 | 2.008.489.843 | 53.54% |
| 2021 | 2.189.589.970 | 8.27% |
| 2022 | 2.253.021.355 | 2.82% |
| 2023 | 2.314.975.432 | 2.68% |
| 2023 | 2.358.563.368 | 1.85% |
| 2024 | 2.357.422.792 | -0.05% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 2005 | 142.905.000 | |
| 2006 | 145.017.000 | 1.46% |
| 2007 | 130.377.000 | -11.23% |
| 2008 | 158.452.000 | 17.72% |
| 2009 | 298.831.000 | 46.98% |
| 2010 | 304.154.000 | 1.75% |
| 2011 | 358.881.000 | 15.25% |
| 2012 | 537.296.000 | 33.21% |
| 2013 | 749.216.000 | 28.29% |
| 2014 | 824.481.000 | 9.13% |
| 2015 | 1.020.265.000 | 19.19% |
| 2016 | 1.120.753.000 | 8.97% |
| 2017 | 1.145.134.000 | 2.13% |
| 2018 | 1.459.363.000 | 21.53% |
| 2019 | 1.564.824.553 | 6.74% |
| 2020 | 2.500.701.037 | 37.42% |
| 2021 | 2.781.172.268 | 10.08% |
| 2022 | 2.976.007.272 | 6.55% |
| 2023 | 3.031.013.175 | 1.81% |
| 2023 | 2.876.687.507 | -5.36% |
| 2024 | 2.848.696.380 | -0.98% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 2005 | 19.178.000 | |
| 2006 | 43.320.000 | 55.73% |
| 2007 | 59.336.000 | 26.99% |
| 2008 | 82.569.000 | 28.14% |
| 2009 | 130.463.000 | 36.71% |
| 2010 | 135.449.000 | 3.68% |
| 2011 | 157.814.000 | 14.17% |
| 2012 | 277.183.000 | 43.07% |
| 2013 | 183.291.000 | -51.23% |
| 2014 | 148.062.000 | -23.79% |
| 2015 | 254.425.000 | 41.81% |
| 2016 | 247.699.000 | -2.72% |
| 2017 | 252.652.000 | 1.96% |
| 2018 | 466.079.000 | 45.79% |
| 2019 | 631.676.439 | 26.22% |
| 2020 | 492.211.194 | -28.33% |
| 2021 | 591.582.298 | 16.8% |
| 2022 | 722.985.917 | 18.18% |
| 2023 | 716.037.743 | -0.97% |
| 2023 | 515.971.563 | -38.77% |
| 2024 | 490.279.513 | -5.24% |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- 0.71
- Net Income per Share
- 0.11
- Price to Earning Ratio
- 92.73x
- Price To Sales Ratio
- 1.77x
- POCF Ratio
- 49.48
- PFCF Ratio
- 8.38
- Price to Book Ratio
- 4.35
- EV to Sales
- 0.11
- EV Over EBITDA
- 0.68
- EV to Operating CashFlow
- 0.4
- EV to FreeCashFlow
- 0.54
- Earnings Yield
- 0.01
- FreeCashFlow Yield
- 0.12
- Market Cap
- 1,29 Bil.
- Enterprise Value
- 0,08 Bil.
- Graham Number
- 2.34
- Graham NetNet
- 1.15
Income Statement Metrics
- Net Income per Share
- 0.11
- Income Quality
- 1.87
- ROE
- 0.05
- Return On Assets
- 0.04
- Return On Capital Employed
- 0.03
- Net Income per EBT
- 0.89
- EBT Per Ebit
- 1.94
- Ebit per Revenue
- 0.09
- Effective Tax Rate
- -0.03
Margins
- Sales, General, & Administrative to Revenue
- 0.16
- Research & Developement to Revenue
- 0.37
- Stock Based Compensation to Revenue
- 0
- Gross Profit Margin
- 0.89
- Operating Profit Margin
- 0.09
- Pretax Profit Margin
- 0.17
- Net Profit Margin
- 0.15
Dividends
- Dividend Yield
- 0.01
- Dividend Yield %
- 0.91
- Payout Ratio
- 1.31
- Dividend Per Share
- 0.09
Operating Metrics
- Operating Cashflow per Share
- 0.2
- Free CashFlow per Share
- 0.15
- Capex to Operating CashFlow
- 0.26
- Capex to Revenue
- 0.07
- Capex to Depreciation
- 2.59
- Return on Invested Capital
- 0.03
- Return on Tangible Assets
- 0.04
- Days Sales Outstanding
- 284.15
- Days Payables Outstanding
- 65.08
- Days of Inventory on Hand
- 343.05
- Receivables Turnover
- 1.28
- Payables Turnover
- 5.61
- Inventory Turnover
- 1.06
- Capex per Share
- 0.05
Balance Sheet
- Cash per Share
- 1,18
- Book Value per Share
- 2,28
- Tangible Book Value per Share
- 2.2
- Shareholders Equity per Share
- 2.27
- Interest Debt per Share
- 0.01
- Debt to Equity
- 0.01
- Debt to Assets
- 0
- Net Debt to EBITDA
- -9.91
- Current Ratio
- 3.88
- Tangible Asset Value
- 2,28 Bil.
- Net Current Asset Value
- 1,38 Bil.
- Invested Capital
- 1980144463
- Working Capital
- 1,39 Bil.
- Intangibles to Total Assets
- 0.03
- Average Receivables
- 0,55 Bil.
- Average Payables
- 0,01 Bil.
- Average Inventory
- 65793910
- Debt to Market Cap
- 0.01
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|---|---|
| 2021 | 0 | |
| 2022 | 0 | 0% |
| 2023 | 0 | 0% |
| 2024 | 0 | 0% |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Profile
About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.
- CEO
- Mr. Da Jun Zhao
- Employee
- 913
- Address
-
Zhangjiang Hi-Tech Park
Shanghai, 201210
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Ms. Dai Qing Yu Deputy General Manager |
70 |
| 2 |
Mr. Luo Chun Wang Core Technical Personnel |
70 |
| 3 |
Ms. Xiaowen Li Deputy General Manager |
70 |
| 4 |
Mr. Jun Li Co-Founder & Deputy GM |
70 |
| 5 |
Ms. Xue Yan ACCA, CIA, CICPA, FCCA, HKICPA Chief Financial Officer, Deputy GM, Company Secretary & Director |
70 |
| 6 |
Mr. Yu Chen Deputy General Manager |
70 |
| 7 |
Mr. Da Jun Zhao Co-Founder, GM & Chairman |
70 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Competitors
